Valeant Pharmaceuticals Intl Inc. Tries to Downplay the Drug-Pricing Scandal

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) has been caught up in a drug-pricing scandal. What are the long-term implications for the stock?

| More on:
The Motley Fool

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) has been hit hard by allegations of drug pricing, driving the stock down 40% over the past month. Chief Executive Officer Michael Pearson says the company plans to reduce its reliance on drugs, whose prices have been substantially raised, all the while insisting that his company has not been involved in unfair drug pricing.

“The pharmaceutical industry is being aggressively attacked for past pricing actions–not just Valeant, but all companies,” Pearson said in a conference call following the company’s latest earnings report. “Given the environment, the pricing that pharmaceutical companies will take in will be more modest,” he added, suggesting a maximum 10% increase in the future.

The company said that during the next 12 months it will consider selling or privatizing its neurology and “other” drug categories, in which much of the “mispriced” buying has occurred; it’s a small part of Valeant’s business, according to Pearson.

Evercore ISI analyst Umer Raffat said because the drugs in question represent only about 10% of Valeant’s revenues, his outlook for the company remains unchanged. “If you take out neuro and ‘other’, which they may potentially divest, it actually makes the volume price even lesser to the overall business,” he said in a note to clients. “It’s not a big part of their business, and that’s the most important thing.”

So, why is the stock dropping like a stone? Well, even though the company insists its involvement in the drug-pricing scandal is minimal, the U.S. Attorney’s offices in Massachusetts and New York have issued court orders forcing Valeant to turn over documents tied to the U.S. price hikes of two heart drugs.

In the U.S. prices for Nitropress and Isuprel increased by 212% and 525% after the company acquired the rights to sell them. Despite Pearson’s attempts to soothe the market, investors hate uncertainty, and that’s just what this scandal has produced.

This week CIBC World Markets cut its price target on the U.S. version of the stock to $200 from $275, citing the company’s statement that the price of drugs will moderate.

The scandal overwhelmed Valeant’s mainly positive earnings for the third quarter, which were released on Monday. The company’s net income rose to $2.74 per share in the third quarter, up from $2.11 in the third quarter of 2014. Revenue rose to $2.78 billion, just above estimates of $2.77 billion.

The problem for Valeant is that even if it has cleaned up its act over drug pricing, the story could remain high profile as it wends its way through the U.S. court system. For long-term investors, this could be a buying opportunity. But it comes with risk if the courts ultimately sanction Valeant.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Doug Watt has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

Daffodils in bloom
Tech Stocks

2 Best “Magnificent Seven” Stocks to Buy in April

Two surging mega-cap tech stocks are the best buys among the “Magnificent Seven” this April.

Read more »

A golden egg in a nest
Stocks for Beginners

Got $5,000? 5 Stocks to Buy for Lasting Wealth

Got $5,000 to build a long-term compounding stock portfolio? Here are five top Canadian stocks to building lasting lifetime wealth.

Read more »

Businessman looking at a red arrow crashing through the floor
Dividend Stocks

BCE’s Stock Price Has Fallen to its 10-Year Low of $44: How Low Can it Go?

BCE stock price has dipped 39% in two years and shows no signs of growth in the next few months.…

Read more »

Dollar symbol and Canadian flag on keyboard
Dividend Stocks

Invest $10,000 in This Dividend Stock for $3,974.80 in Passive Income

This dividend stock gives you far more passive income than just from dividends alone, so consider it if you want…

Read more »

Payday ringed on a calendar
Dividend Stocks

This 6% Dividend Stock Pays Cash Every Month

Can a 6% dividend yield help you build a monthly retirement income? An investment made right can help you build…

Read more »

Payday ringed on a calendar
Dividend Stocks

Passive Income: How Much Should You Invest to Earn $1,000 Every Month?

These three monthly-paying dividend stocks can help you earn a monthly passive income of $1,000.

Read more »

clock time
Tech Stocks

Up 47%, Is it Time to Buy Payfare Stock?

Payfare (TSX:PAY) stock has been rising higher in the last six months after dropping significantly since 2021. Is it time…

Read more »

Dividend Stocks

3 Dividend Stocks to Double Up on Right Now

Some of these dividend stocks will take longer to recover than others, but they'll certainly pay you to stick around.

Read more »